Top Clinical Trials companies in the world by Net Income Margin

This ranking features the top 353 Clinical Trials companies in the world ranked by Net Income Margin, averaging a Net Income Margin of -5,608,649.41%, for January 15, 2025.

Global

Clinical Trials

#	Name	Net Income Margin	Reported Date	Stock Price	Change	Country
1	Inhibrx Biosciences, Inc. 1 INBX	94,684.72%	Sept. 30, 2024	USD 12.74	-6.60%	United States
2	Eledon Pharmaceuticals, Inc. 2 ELDN	2,168.39%	Sept. 30, 2024	USD 3.71	-4.63%	United States
3	Oramed Pharmaceuticals Inc. 3 ORMP	1,551.34%	March 31, 2024	USD 2.36	NA	United States
4	Immuneering Corporation 4 IMRX	1,085.06%	Sept. 30, 2023	USD 1.95	-2.99%	United States
5	Alar Pharmaceuticals Inc. 5 6785.TWO	81.53%	Dec. 31, 2023	USD 4.09	5.18%
6	Protagonist Therapeutics, Inc. 6 PTGX	52.76%	Sept. 30, 2024	USD 36.67	-1.26%	United States
7	Akeso, Inc. 7 9926.HK	44.81%	Dec. 31, 2023	USD 7.28	2.32%	China
8	BioArctic AB (publ) 8 BIOA-B.ST	37.22%	Dec. 31, 2023	USD 17.87	3.09%	Sweden
9	GNI Group Ltd. 9 2160.T	31.12%	Dec. 31, 2023	USD 19.77	1.11%	Japan
10	hVIVO plc 10 HVO.L	28.75%	Dec. 31, 2023	USD 0.21	6.16%	United Kingdom
11	Hangzhou Tigermed Consulting Co., Ltd. 11 3347.HK	27.42%	Dec. 31, 2023	USD 3.72	2.09%	China
12	Genmab A/S 12 GMAB.CO	26.42%	Dec. 31, 2023	USD 216.88	1.28%	Denmark
13	HBM Holdings Limited 13 2142.HK	25.47%	Dec. 31, 2023	USD 0.34	-0.77%	China
14	BioNTech SE 14 22UA.F	24.36%	Dec. 31, 2023	USD 116.36	-0.45%	Germany
15	Corcept Therapeutics Incorporated 15 CORT	22.48%	Sept. 30, 2024	USD 51.66	1.18%	United States
16	Exelixis, Inc. 16 EXEL	22.43%	Sept. 27, 2024	USD 35.65	0.99%	United States
17	Krystal Biotech, Inc. 17 KRYS	21.68%	Sept. 30, 2024	USD 142.64	-5.10%	United States
18	Shin Nippon Biomedical Laboratories, Ltd. 18 2395.T	20.91%	March 31, 2024	USD 10.78	1.91%	Japan
19	Mega Genomics Limited 19 6667.HK	19.85%	Dec. 31, 2023	USD 1.18	-0.89%	China
20	Medpace Holdings, Inc. 20 MEDP	17.65%	Sept. 30, 2024	USD 330.91	-5.99%	United States
21	Neurocrine Biosciences, Inc. 21 NBIX	17.21%	Sept. 30, 2024	USD 139.51	-2.46%	United States
22	Joinn Laboratories(China)Co.,Ltd. 22 6127.HK	16.71%	Dec. 31, 2023	USD 1.06	2.98%	China
23	Voyager Therapeutics, Inc. 23 VYGR	15.80%	Sept. 30, 2024	USD 5.05	-4.36%	United States
24	Vimta Labs Limited 24 VIMTALABS.NS	12.89%	March 31, 2024	USD 10.54	-1.07%	India
25	HUTCHMED (China) Limited 25 0013.HK	12.03%	Dec. 31, 2023	USD 3.02	2.59%	Hong Kong
26	Precision BioSciences, Inc. 26 DTIL	11.48%	Sept. 30, 2024	USD 5.38	-6.27%	United States
27	CytomX Therapeutics, Inc. 27 CTMX	10.92%	Sept. 30, 2024	USD 0.84	-5.23%	United States
28	Charles River Laboratories International, Inc. 28 CRL	10.17%	Sept. 28, 2024	USD 178.08	-6.34%	United States
29	Shanghai Henlius Biotech, Inc. 29 2696.HK	10.12%	Dec. 31, 2023	USD 2.59	-10.24%	China
30	Supernus Pharmaceuticals, Inc. 30 SUPN	9.16%	Sept. 30, 2024	USD 37.82	0.66%	United States
31	Cytori Cell Research Institute, Inc. 31 3750.T	8.85%	March 31, 2024	USD 5.61	0.04%	Japan
32	ICON Public Limited Company 32 ICLR	7.54%	Dec. 31, 2023	USD 200.24	-8.14%	Ireland
33	Sarepta Therapeutics, Inc. 33 SRPT	7.43%	Sept. 30, 2024	USD 118.83	0.34%	United States
34	StemRIM 34 4599.T	7.16%	July 31, 2023	USD 1.94	-0.83%	Japan
35	Kindstar Globalgene Technology, Inc. 35 9960.HK	4.27%	Dec. 31, 2023	USD 0.15	-0.02%	China
36	Australian Clinical Labs Limited 36 ACL.AX	3.47%	June 30, 2024	USD 2.14	0.82%	Australia
37	Rigel Pharmaceuticals, Inc. 37 RIGL	2.46%	Sept. 30, 2024	USD 16.69	-2.46%	United States
38	Castle Biosciences, Inc. 38 CSTL	1.95%	Sept. 30, 2024	USD 25.46	-2.64%	United States
39	PhoenixBio Co., Ltd. 39 6190.T	1.54%	March 31, 2024	USD 2.06	-4.87%	Japan
40	Telix Pharmaceuticals Limited 40 TLX.AX	1.05%	Dec. 31, 2023	USD 15.47	4.25%	Australia
41	Incyte Corporation 41 INCY	0.80%	Sept. 30, 2024	USD 71.93	-0.61%	United States
42	ABL Bio Inc. 42 298380.KQ	-4.04%	Dec. 31, 2023	USD 21.07	1.40%	South Korea
43	Cingulate Inc. 43 CING	-4.48%	Sept. 30, 2023	USD 4.62	-0.22%	United States
44	Vertex Pharmaceuticals Incorporated 44 VRTX	-4.52%	Sept. 30, 2024	USD 411.66	-0.41%	United States
45	TOT BIOPHARM International Company Limited 45 1875.HK	-4.84%	Dec. 31, 2023	USD 0.24	4.98%	China
46	TG Therapeutics, Inc. 46 TGTX	-5.42%	Sept. 30, 2024	USD 29.74	7.48%	United States
47	Corline Biomedical AB 47 CLBIO.ST	-7.23%	Dec. 31, 2023	USD 0.84	-0.17%	Sweden
48	Lepu Biopharma Co., Ltd. 48 2157.HK	-9.81%	Dec. 31, 2023	USD 0.31	4.82%	China
49	Purple Biotech Ltd. 49 PPBT.TA	-10.15%	Dec. 31, 2023	USD 0.02	-1.36%	Israel
50	NeoGenomics, Inc. 50 NEO	-12.07%	Sept. 30, 2024	USD 13.78	9.11%	United States

1 2 3 4 … 8

Frequently Asked Questions

Which Clinical Trials company has the highest Net Income Margin ?

The Clinical Trials company with the highest Net Income Margin is Inhibrx Biosciences, Inc. (NasdaqGS: INBX) at 94,684.72%.
Which Clinical Trials company has the lowest Net Income Margin ?

The Clinical Trials company with the lowest Net Income Margin is Inhibikase Therapeutics, Inc. (NasdaqCM: IKT) at -1,956,524,900.00%.

What are the top 10 Clinical Trials companies by Net Income Margin ?

The top 10 Clinical Trials companies the Global by Net Income Margin are Inhibrx Biosciences, Inc., Eledon Pharmaceuticals, Inc., Oramed Pharmaceuticals Inc., Immuneering Corporation, Alar Pharmaceuticals Inc., Protagonist Therapeutics, Inc., Akeso, Inc., BioArctic AB (publ), GNI Group Ltd. and hVIVO plc.
What are the bottom 10 Clinical Trials companies by Net Income Margin ?

The bottom 10 Clinical Trials companies by Net Income Margin are Inhibikase Therapeutics, Inc., ZyVersa Therapeutics, Inc., BrightPath Biotherapeutics Co., Ltd., Summit Therapeutics Inc., Allogene Therapeutics, Inc., OncoZenge AB (publ), Immix Biopharma, Inc., Cadrenal Therapeutics, Inc. Common Stock, NRx Pharmaceuticals, Inc. and Altimmune, Inc..